TD Waterhouse Canada Inc. Purchases 15,024 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

TD Waterhouse Canada Inc. grew its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 601.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 17,524 shares of the company's stock after purchasing an additional 15,024 shares during the period. TD Waterhouse Canada Inc.'s holdings in Hims & Hers Health were worth $424,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of HIMS. Means Investment CO. Inc. raised its stake in Hims & Hers Health by 23.5% during the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after purchasing an additional 9,508 shares during the period. Principal Financial Group Inc. increased its holdings in Hims & Hers Health by 102.0% in the 3rd quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock worth $5,349,000 after buying an additional 146,621 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $18,048,000. State of Alaska Department of Revenue purchased a new stake in Hims & Hers Health during the fourth quarter worth $2,628,000. Finally, Pacer Advisors Inc. purchased a new position in Hims & Hers Health during the fourth quarter valued at $374,000. 63.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 4,153 shares of Hims & Hers Health stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $35.30, for a total transaction of $146,600.90. Following the completion of the sale, the insider now owns 161,497 shares in the company, valued at approximately $5,700,844.10. This trade represents a 2.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 100,000 shares of the company's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the completion of the transaction, the chief executive officer now owns 27,918 shares of the company's stock, valued at $983,271.96. This trade represents a 78.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 766,234 shares of company stock valued at $29,909,645. Insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Up 6.1 %

Shares of HIMS traded up $2.02 during trading hours on Thursday, hitting $35.12. The company had a trading volume of 20,101,111 shares, compared to its average volume of 16,477,019. The business has a fifty day moving average of $32.49 and a 200-day moving average of $31.19. The firm has a market cap of $7.80 billion, a price-to-earnings ratio of 79.19 and a beta of 1.65. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on HIMS. Morgan Stanley cut their price objective on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective on the stock. Truist Financial cut their price target on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Piper Sandler lifted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $36.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.